Association of atopic dermatitis with migraine: A systematic review and meta-analysis
Abstract
Abstract Background: Increasing evidence suggested a link between atopic dermatitis (AD) and migraine. However, a comprehensive analysis on the association of AD with migraine was lacking. Objectives: To systematically analyze the best evidence regarding the association between AD and migraine. Methods: We performed a systematic review and searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials databases from inception until August 18, 2024. Case–control and cohort studies evaluating the odds or risk of migraine in AD patients were included. A random-effects model meta-analyses were employed to estimate the pooled odds or risk of migraine. Subgroup analyses based on AD severity were conducted, along with a sensitivity analysis for migraine. Results: We included nine case–control and three cohort studies with a total of 15,107,821 subjects. The meta-analysis revealed a significant association between AD and the prevalence of migraine (odds ratio [OR] 1.64; 95% confidence intervals [CI] 1.38–1.94). AD patients also had an increased risk of incident migraine (hazard ratio 1.21; 95% CI 1.14–1.29). A subgroup analysis demonstrated that patients with severe AD had higher odds of prevalent migraine (OR 2.69; 95% CI 1.63–4.46) than those with mild AD (OR 1.63; 95% CI 1.39–1.92). Conclusion: Patients with AD, especially those with severe AD, have an increase in comorbid prevalent and incident migraine. Increased awareness of headache symptoms in AD patients can…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 15,107,821 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.